Omega-3FAs Can Inhibit the Inflammation and Insulin Resistance of Adipose Tissue Caused by HHcy Induced Lipids Profile Changing in Mice

Jing Li1, Heng Zhang1, Yongqiang Dong2, Xian Wang2 and Guang Wang1*

1 Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China, 2 Key Laboratory of Molecular Cardiovascular Science, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Ministry of Education, Peking University, Beijing, China

The adipose Nod-like receptor protein 3 (NLRP3) inflammasome initiates insulin resistance; however, the mechanism of inflammasome activation in adipose tissue remains elusive. In this study, homocysteine (Hcy) was found to participate in insulin resistance via a NLRP3 inflammasome-related process. Hcy-induced activation of NLRP3 inflammasomes were observed in adipose tissue during the generation of insulin resistance in vivo. This animal model suggests that diets high in omega-3 fatty acids alter serum and adipose lipid profiles, and in this way, omega-3 fatty acids may reduce adipose tissue inflammation and attenuate insulin resistance.

Keywords: insulin resistance, homocysteine, adipocyte, omega-3 fatty acids, inflammation

INTRODUCTION

Insulin resistance plays a key role in the metabolic syndrome, which includes diabetes, obesity-related atherosclerosis, and lipid disorders (Petersen and Shulman, 2018). Previously, we reported that hyperhomocysteinemia (HHcy) was an independent risk factor for development of insulin resistance (Li Y. et al., 2013). This was confirmed in studies both in humans and in a rodent model. Omega-3 fatty acids (ω-3FAs), primarily eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), exert anti-inflammatory activities in a variety of inflammatory diseases, including obesity, diabetes, atherosclerosis, as well as other metabolic inflammatory disorders (Tortosa-Caparrós et al., 2017). Fish oil, which contains ω-3FAs, is thought to participate in lowering serum concentrations of lipids (Nicholls et al., 2018). In another study, n-3 polyunsaturated fatty acids (PUFAs) regulated hepatic genes such as peroxisome proliferators-activated receptors-alpha (PPAR-alpha) and sterol-regulatory element binding protein-1 (SREBP-1). This may modestly raise hepatic glucose production while also reducing hyperinsulinemia, but without causing peripheral insulin resistance or systemic metabolic dysfunction (Devarshi et al., 2013). In animal models, expression of such kinds of lipids biosynthesis related genes in the liver reduce hepatic steatosis (Rosmeisl et al., 2014). Nevertheless, the mechanisms by which ω-3FAs reduce adipose insulin resistance remain poorly understood.
Homocysteine (Hcy) is a sulfur-containing non-proteinogenic amino acid. Increased plasma Hcy levels [to more than 15 μM, defined as hyperhomocysteinemia (HHcy)] is an independent risk factor for cardiovascular disease and other metabolic inflammation diseases (Hainsworth et al., 2016). Patients with insulin resistance and type 2 diabetes mellitus were found to have increased plasma levels of Hcy (Li et al., 2008; Kundt et al., 2017). Treatments that lower plasma Hcy levels, including folic acid, might improve insulin sensitivity; dietary supplementation vitamin B are more effective in preventing metabolic syndrome and related vascular disease in areas where the population has a normally low folate consumption than in areas with higher dietary folate intake (Earnest et al., 2012). Our previous studies established that mice treated with oral Hcy mimic the increase of atherosclerosis and other general phenotypes in patients with HHcy (Dai et al., 2006). HHcy increases oxidative stress and its downstream signaling pathways, resulting in vascular inflammation stress and endoplasmic reticulum stress (Fu et al., 2018; Majumder et al., 2018). In a mouse model of HHcy, Hcy was enriched in adipose tissue, promoting insulin resistance and metabolic inflammation (Li et al., 2008; Li Y. et al., 2013).

We found that increased plasma levels of Hcy promotes insulin resistance by activating adipocyte and adipose tissue macrophage Nod-like receptor protein 3 inflammasomes (NLRP3). The NLRP3 inflammasome is also involved in Hcy-induced adipose insulin resistance; Hcy acted as a second signal activator of the adipocyte NLRP3 inflammasome, and the adipocyte inflammation participates in lipid disorders and insulin resistance (Zhang et al., 2018). Nevertheless, it remains unknown as to whether ω-3FA intake attenuates adipose metabolic inflammation.

Therefore, in the present study, we focused on whether ω-3FA consumption would attenuate HHcy-induced insulin resistance and tried to explain the mechanism through the histochemical changes caused by ω-3FAs.

We used ultraperformance liquid chromatography coupled to electrospray ionization quadrupole mass spectrometry (UPLC-ESI-QTOFMS)-based metabolomics analysis to measure the changes of bioactive metabolites in HHcy mice undergoing ω-3FA treatment.

**MATERIALS AND METHODS**

**Animals and Housing**
All mice were housed under specific pathogen-free conditions in a temperature-controlled room (22°C) with a 12-h light and dark cycle and were given free access to normal chow diet (Cat. 1025, HFK Biosciences, Beijing, China) and drinking water. Wild type (WT) mice were generated from the C57BL/6J background (33 mg/g) diet. After 6 weeks, mice were sacrificed, and the metabolic profiles of the adipose tissue were analyzed using UPLC-ESI-QTOFMS-based lipidomics. Expression levels of ceramide metabolism-related genes were measured using quantitative PCR. DL-Hcy was purchased from Sigma-Aldrich Chemicals (Cat. H4628, St. Louis, MO, United States).

**Glucose Tolerance Test and Insulin Tolerance Test**
For the glucose tolerance test (GTT), mice were fasted for 12 h before the administration of glucose (1.8 g/kg, i.p.). Blood samples were drawn from a cut at the tip of the tail at 0, 30, 60, 90, and 120 min after glucose administration, and blood glucose concentrations were measured immediately. For the insulin tolerance test (ITT), mice were fasted for 4 h before the administration of insulin (1 IU/kg, i.p.). Blood samples were drawn from a cut at the tip of the tail at 0, 30, 60, 90, and 120 min after insulin administration, and blood glucose concentrations were measured immediately.

**Immunohistochemistry**
F4/80 (Cat.ab16911, Abcam, Abcam Cambridge, United Kingdom) expression in adipose tissue was examined by immunohistochemistry using 7-μm sections of the eWAT. The sections were blocked with 5% bovine serum albumin (BSA) for 1 h and incubated overnight at 4°C with F4/80 antibody (1:500). After washing, the sections were incubated with the Horseradish Peroxidase (HRP)-conjugated anti-rabbit IgG (Cat. sc-2004, Santa Cruz, Dallas, TX, United States) secondary antibody (1:1000) for 1 h. The DAB method was used to detect the F4/80 signal.

**Lipidomics Analysis**
The serum and adipose sample preparations and the lipidomics analyses were undertaken as described previously (Jiang et al., 2015). In brief, epididymal white adipose tissue (eWAT) (20 mg) were homogenized with ultrapure water (200 μl) and then extracted with chloroform-methanol (2:1) solution (1,000 μl). The samples were incubated at 37°C for 30 min and subsequently centrifuged at 16,000 g for 20 min at 4°C. The lower organic phase (approximately 500 μl) was collected and evaporated. The organic residue was dissolved in isopropanol-acetonitrile (1:1) solution (100 μl). Samples were analyzed using the Thermo Scientific Dionex UltiMate 3000 Rapid Separation LC system (Thermo Fisher Scientific, Waltham, MA, United States). Peak extraction and integration were performed using Xcalibur 2.2 SP1.48 software (Thermo Fisher Scientific, Waltham, MA, United States).

**Western Blot**
Total protein was isolated with RIPA lysis buffer (Cat. P0013C, Beyotime Biotechnology, Shanghai, China). Total protein was subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis on 10 or 12% running gels and then transferred to polyvinylidene fluoride membranes. The membranes were incubated with 10% BSA in Tris Tween-buffered saline at room
temperature for 1 h, with various primary antibodies at 4°C for 12 h and with a HRP-conjugated secondary antibody for 1.5 h. The bands were exposed using the ChemiDIOC XRS System (Bio-Rad, Hercules, CA, United States). Anti-NLRP3 (Cat. AF-401-NA) antibody was purchased from R&D Systems (Minneapolis, MN, United States). Anti-β-actin (Cat. 8457) antibody was purchased from Cell Signaling Technology (Danvers, MA, United States). The HRP-conjugated anti-rabbit IgG (Cat. sc-2004), HRP-conjugated anti-goat IgG (Cat. sc-2020), and HRP-conjugated anti-mouse IgG (Cat. sc-2005) secondary antibodies were all purchased from Santa Cruz Biotechnology (Dallas, TX, United States).

Quantitative PCR Measurement of mRNA Levels
Total RNA was isolated using TRIzol Reagent (Cat. 15596018, Thermo Fisher Scientific, Waltham, MA, United States). Total RNA (2 μg) was reverse transcribed using 5X All-In-One RT MasterMix (Cat. G490, abm, Richmond, BC, Canada). Quantitative PCR (qPCR) analysis was performed using RealStar Green Power Mixture (Cat. A314, GenStar, Beijing, China) and run on an Mx3000 Multiplex Quantitative PCR System (Agilent, La Jolla, CA, United States). The amount of the PCR products formed in each cycle was evaluated using the fluorescence of SYBR Green I. The results were analyzed using Stratagene Mx3000 software. The qPCR primer sequences are shown in Table 1.

Statistical Analysis
The data were expressed as means ± SD and were analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA, United States). For metabolomics analysis, the data were analyzed using MetaboAnalyst 3.0. One-way ANOVA with Tukey’s multiple comparisons test (between multiple groups) and unpaired Student’s t test (between two groups) were used as appropriate. P < 0.05 was considered significant.

RESULTS
ω-3FAs Treatment Improves Hcy-Induced Insulin Resistance in a Mouse Model
To investigate the precise mechanisms underlying the effects fish oil on Hcy-induced insulin resistance, WT mice were given Hcy with or without fish oil in the drinking water (Hcy 1.8 g/l, ω-3FAs 3.3%, 6 weeks). IPGTT and ITT revealed marked glucose intolerance and insulin resistance in the Hcy-treated mice (Figures 1A,B), while the body weights were not significantly different from those of controls after fish oil treatment (Figure 1C).

ω-3FAs Intake Decreases the Production of Sphingolipids and Free Fatty Acids in Serum and Changes the Lipid Profile of Adipose Tissue Under Normal Diet
To further characterize the exact lipid profile changes because of ω-3FAs treatment, a non-targeted lipidomics assay was performed in serum. ω-3FAs intake decreased the production of sphingolipids and free fatty acids in fat tissue under normal diet (n = 7 per group) (Figures 2A–D). A heatmap of sphingolipids and FAs revealed increased lyso-PC and PUFA levels in the adipose tissue of Hcy-treated mice that represents a lipid metabolic pattern distinct from that of vehicle-treated mice after ω-3FAs intake (Figure 3).

ω-3FAs Supplementation Significantly Changes the Lipid Profile in Adipose Tissue
Levels of lyso-PC (16:0), lyso-PC (18:0), lyso-PC (18:1), PC (16:0-22:6), PC (18:1-14:0), PC (18:1-20:4), PC (18:1-22:6), PC (18:0-20:5), PC (16:0-20:0), FA (20:4), and FA (22:4) were altered by Hcy treatment while tending to remain normal after ω-3FAs intake (Figures 4A–C). The generation of lyso-PC and PUFA depends on phospholipase A2 (PLA2), which hydrolyzes the sn-2 position of phosphatidylcholine (PC) (Murakami et al., 2011). In agreement with the lipidomics data, PLA2 activity was elevated in the adipose tissue of Hcy-treated mice that is distinct from that of vehicle-treated mice after ω-3FAs intake (Figure 4D).

ω-3FAs Attenuate Hcy-Induced NLRP3 Inflammasome Activation in Adipose Tissue
Homocysteine was previously shown to increase the HIF1α protein levels in podocytes (Li C. et al., 2013). Increased HIF1α levels, and the glycolysis-associated genes, PDK1 and Glut1 mRNA level were also observed in the adipose tissue of Hcy-treated mice (Figure 4D). PLA2G16 is a PLA2 and is a PLA2 activity was elevated in the adipose tissue of Hcy-treated mice (Figure 4D).
Li et al. Omega-3FAs and Adipose Tissue

FIGURE 1 | ω-3FAs treatment improves Hcy-induced insulin resistance in a mouse model. (A) Plasma glucose levels of Intraperitoneal glucose tolerance test (IPGTT) in a mouse model (n = 7). (B) Plasma glucose levels of insulin tolerance test (ITT) in a mouse model (n = 7). (C) Body weight in the mouse model (n = 7). All data are presented as the means ± SD. * P < 0.05 vs. control group, # P < 0.05 vs. HHcy group; mice given Hcy (1.8 g/l), ω-3FAs (3.3%) in the drinking water for 6 weeks.

FIGURE 2 | ω-3FAs intake decreases the production of sphingolipids and free fatty acids in serum and adipose under normal diet. (A) Lipidomics analysis of the abundance of serum ceramide under normal diet. (B) Lipidomics analysis of the abundance of serum sphingomyelins under normal diet. (C) Lipidomics analysis of the abundance of serum carnitine under normal diet. (D) Lipidomics analysis of the abundance of serum free fatty acids under normal diet. * P < 0.05 vs control group, ** P < 0.01 vs control group, n = 7.

highly expressed in Hcy-induced insulin resistance mice while levels of PDK1 and Glut1 decreased (Figure 4D). Protein levels of NLRP3 and Act-Casp1 were measured using western blotting. After Hcy treatment, NLRP3 levels were elevated in adipose tissue, and ω-3FAs inhibited levels of Hcy-up-regulated inflammatory markers (Figure 5A). In order to verify that fish oil treatment can improve the inflammation in adipose tissue, we carried out the immunohistochemistry of adipose tissue.
FIGURE 3 | Heatmap of phospholipids and FAs in the adipose tissue of Hcy-treated mice. Seven-week-old WT mice were fed normal chow diet and were given Hcy (1.8 g/L) or vehicle in the drinking water with or without ω-3FA (3.3%) for 6 weeks.

The results showed that after 6 weeks of ω-3FAs treatment, the expression of F4/80 in adipose tissue of mice decreased, indicating that the inflammation of adipose tissue was alleviated (Figure 5B).

DISCUSSION

Clinical trials assessing effect of ω-3FAs in primary and secondary prevention of cardiovascular disease have produced conflicting findings. Fish oil rich in ω-3FAs supplements have been widely used and recommended for prevention and treatment of lipid disorders and metabolic disease, and the clinical utility of ω-3FAs in lowering triglyceride levels is well known (Mansoori et al., 2015). There is also evidence suggesting that the Mediterranean diet supports addition of fish to the diet for prevention of cardiovascular disease (Guasch-Ferré et al., 2017). Mechanisms by which ω-3FAs exert their anti-inflammatory effects are not fully understood.

Homocysteine and C2-ceramide cause murine cerebral endothelial cells metabolic disorder by activating the Asm-ceramide pathway (Lee et al., 2013). Oxidative stress and de novo ceramide synthesis could induce NLRP3-inflammasome activation. It was found that ω-3FAs reduced nuclear factor kappa B-mediated inflammation in the liver through effects on inflammasome signaling (Feng et al., 2018). One study in 3T3-L1 adipocytes suggested that inhibition of IL-18, IL-1β, and caspase-1 by DHA and EPA were predominantly dependent upon adiponectin (Oster et al., 2010). These findings suggest that Hcy might induce inflammation and ω-3FAs might attenuate
Li et al. Omega-3FAs and Adipose Tissue

FIGURE 4 | ω-3FAs supplementation significantly changes the lipid profile of adipose tissue. (A) Lipidomics analysis of the lyso-PC profile of mouse adipose tissue; (n = 6 per group). (B) Lipidomics analysis of the PC profile of mouse adipose tissue; (n = 6 per group). (C) Lipidomics analysis of the FA profile of mouse adipose tissue; (n = 6 per group). Seven-week-old WT mice were fed normal chow diet and were given Hcy (1.8 g/L) or vehicle in the drinking water with or without ω-3FAs (3.3%) for 6 weeks. Two-tailed Student’s t-test: *P < 0.05 vs. control group, #P < 0.05 vs. HHcy group. (D) qPCR analysis of mRNA levels of HIF-1, PDK1, Glut1, and Pla2g16 in mouse adipose tissue; (n = 6 per group).
Figure 5 | Activation of the Hcy-induced NLRP3 inflammasome was attenuated by ω-3FAs in adipose tissue. (A) Western blot analysis of Act-CASP1 and NLRP3 protein levels in adipose tissue; (B) Immunohistochemical study of inflammation related molecule F4/80 in mouse adipose tissue, (n = 6 per group). Seven-week-old WT mice were fed normal chow diet and were given Hcy (1.8 g/L) or vehicle in the drinking water with or without ω-3FAs (3.3%) for 6 weeks. Two-tailed Student’s t-test: *P < 0.05 vs. control group, #P < 0.05 vs. HHcy group, n = 7.

The inflammation as well as insulin resistance as shown in the present study.

Because the NLRP3 inflammasome is activated in human mesenchymal stem cells via lipopolysaccharide and palmitic acid, and plasma (Fu et al., 2019) levels are increased in the context of obesity (Wang et al., 2017), Hcy might be one of the mediators involved in obesity-induced insulin resistance. Oral intake of ω-3FAs as a treatment could turn over HHcy-induced lipid profile alterations in adipose tissue, and may modulate inflammation factors that have potential therapeutic functions in reducing adipose tissue inflammation-induced insulin resistance.

We found that the Hcy induced alterations in adipose tissue lipid profiles, confirming findings of our previous study. The NLRP3 inflammasome is activated by HHcy treatment and promotes insulin resistance and adipose inflammation. Increased expression levels of Pla2g16 mRNA as a marker of inflammatory activation are attenuated after ω-3FAs intake, hinting that adipose insulin resistance might be reduced secondary to the lipid profile modifications, especially in adipose tissue.

C12-16 saturated and monounsaturated fatty acids, ceramide, and lyso-PC have been reported to act as second signal activators of the NLRP3 inflammasome (Matsuzaka et al., 2012; Scheiblich et al., 2017; Zhang et al., 2018). Extracellular lyso-PC has been reported to activate G protein-coupled receptors (GPRs), GPR132 and GPR4, mediating its functions (Meyer zu Heringdorf and Jakobs, 2007) and participating in lyso-PC-induced Ca²⁺ influx and immune cell inflammation (Kabarowski, 2009; Khan et al., 2010), which may be involved in lyso-PC-induced NLRP3 inflammasome activation.

In the present study, lyso-PC was found to activate adipose NLRP3 inflammasomes. Lyso-PC also acts as a lipid mediator in
response to inflammation (Kabarowski, 2009). The contrasting effects of lyso-PC on insulin resistance and adipose tissue inflammation may be due to the different species of lyso-PC. These findings support our finding that Hcy might induce inflammation in a lipid profile-affecting manner, and the alteration in the inflammation-inducing lipid profile might be affected by ω-3FAs administration.

Previous studies showed that adipose tissue insulin resistance is often accompanied by activation of inflammasomes due to hyperoxia. PLA2G16 was first recognized as a type II tumor suppressor gene (Sers et al., 1997) and was identified as a PPARγ target gene, expressed specifically in adipose tissue (Hummasti et al., 2008; Uyama et al., 2009). Knockout of Pla2g16 target gene, expressed specifically in adipose tissue (Hummasti et al., 2008; Uyama et al., 2009). Knockout of Pla2g16

We acknowledge that there are limitations to our studies, including the lack of mechanistic data. Our study focused on adipose and may have reflected mixed contributions from cell types populating adipose tissue (i.e., adipocytes, adipose immune cells, adipose progenitor cells, and vasculature). Finally, in this short-term study, prediction of long-term effects and outcomes was not feasible. Despite these limitations, our study adds to the emerging body of knowledge regarding potential beneficial effects of fish oils and their derivatives.

In summary, this study demonstrated that Hcy activates the NLRP3 inflammasomes in adipocytes in a lyso-PC-dependent manner while HHcy induces insulin resistance in adipose tissue. Addition of ω-3FAs in the diet may modulate inflammatory processes.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Animal Care and Use Committee of Capital Medical University.

**AUTHOR CONTRIBUTIONS**

JL designed, performed, analyzed, and interpreted the majority of animal and biochemical experiments, and drafted the manuscript. HZ and YD supported the animal experiments, and performed and analyzed the lipidomics analysis. XW and GW designed, planned, and interpreted the study. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Nos. 81200626 and 81670519) and Beijing Hospitals Authority Youth Program (Nos. QML20170302 and QML20190302). These funders had no role in study design, data interpretation, or writing of the manuscript.

**REFERENCES**

Dai, J., Li, W., Chang, L., Zhang, Z., Tang, C., Wang, N., et al. (2006). Role of redox factor-1 in hyperhomocysteinemia-accelerated atherosclerosis. Free Radic. Biol. Med. 41, 1566–1577. doi: 10.1016/j.freeradbiomed.2006.08.020

Devarshi, P. P., Jangale, N. M., Ghule, A. E., Bodhankar, S. L., and Hansulkar, A. M. (2013). Beneficial effects of flaxseed oil and fish oil diet are through modulation of different hepatic genes involved in lipid metabolism in streptozotocin-nicotinamide induced diabetic rats. Genes Nutr. 8, 329–342. doi: 10.1007/s12263-012-0326-2

Duncan, R. E., Sarkadi-Nagy, E., Jaworski, K., Ahmadian, M., and Sul, H. S. (2008). Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J. Biol. Chem. 283, 25428–25436. doi: 10.1074/jbc.m804146200

Earnest, C. P., Kupper, J. S., Thompson, A. M., Guo, W., and Church, T. (2012). Complementary effects of multivitamin and omega-3 fatty acid supplementation on indices of cardiovascular health in individuals with elevated homocysteine. Int. J. Vitam. Nutr. Res. 82, 41–52. doi: 10.1024/0300-9831/a000093

Feng, R., Wang, Y., Liu, C., Yan, C., Zhang, H., Su, H., et al. (2018). Acetaminophen-induced liver injury is attenuated in transgenic fat-1 mice endogenously synthesizing long-chain n-3 fatty acids. Biochem. Pharmacol. 154, 75–88. doi: 10.1016/j.bcp.2018.04.019

Fu, L., Li, Y. N., Luo, D., Deng, S., and Hu, Y. Q. (2019). Plausible relationship between homocysteine and obesity risk via MTHFR gene: a meta-analysis of 38,317 individuals implementing Mendelian randomization.

**Diabetes Metab. Syndr. Obes.** 12, 1201–1212. doi: 10.2147/dmso.s205379

Fu, Y., Wang, X., and Kong, W. (2018). Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets. Br. J. Pharmacol. 175, 1173–1189. doi: 10.1111/bph.13988

Guasch-Ferré, M., Hu, F. B., Ruiz-Canela, M., Bulló, M., Toledo, E., Wang, D. D., et al. (2017). Plasma metabolites from choline pathway and risk of cardiovascular disease in the PREDIMED (prevention with Mediterranean diet) Study. J. Am. Heart Assoc. 6, e006524.

Hainsworth, A. H., Yeo, N. E., Weekman, E. M., and Wilcock, D. C. (2016). Homocysteine, hyperhomocysteinaemia and vascular contributions to cognitive impairment and dementia (VCID). Biochem. Biophys. Acta 1862, 1008–1017. doi: 10.1016/j.bbadis.2015.11.015

Hummasti, S., Hong, C., Bensinger, S. J., and Tontonoz, P. (2008). HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation. J. Lipid Res. 49, 2535–2544. doi: 10.1194/jlr.m0800269-h04000

Jaworski, K., Ahmadian, M., Duncan, R. E., Sarkadi-Nagy, E., Varady, K. A., Hellerstein, M. K., et al. (2009). AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 15, 159–168. doi: 10.1038/nm.1904

Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., et al. (2015). Omega-3 FAs and Adipose Tissue Inflammation-Inducing Lipid Profile Might Be Affected by PLA2G16 Target Gene, Expressed Specifically in Adipose Tissue (Hummasti et al., 2008; Uyama et al., 2009). Knockout of Pla2g16

Kabarowski, J. H. (2009). G2A and LPC: regulatory functions in immunity. Prostaglandins Other Lipid Mediat. 89, 73–81. doi: 10.1016/j.prostaglandins.2009.04.007
Khan, S. Y., McLaughlin, N. I., Kelher, M. R., Eckels, P., Gamboni-Robertson, F., Banerjee, A., et al. (2010). Lysophosphatidylcholines activate G2A inducing G(αi)−1/G(αq)−11−Ca^2+ flux, G(βγ)−Hck activation and clathrin/β-arrestin-1/GIRK6 recruitment in PMNs. *Biochem. J.* 432, 35−45.

Kundi, H., Kailbun, E., Ates, I., Cetin, M., Barca, A. N., and Oskayr, N., et al. (2017). Association between plasma homocysteine levels and end-organ damage in newly diagnosed type 2 diabetes mellitus patients. *Endocr. Res.* 42, 36−41. doi: 10.3109/07435800.2016.1171235

Lee, J. T., Peng, G. S., Chen, S. Y., Hsu, C. H., Lin, C. C., Cheng, C. A., et al. (2013). Protective role of growth hormone against hyperhomocysteinemia-induced glomerular injury. *Prog. Lipid Res.* 50, 152ñ192. doi: 10.1016/j.plipres.2010.08.007

Majumder, A., Singh, M., Behera, J., Theilen, N. T., George, A. K., Tyagi, N., et al. (2018). Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury. *Am. J. Physiol. Cell Physiol.* 315, C609ñC622.

Meyer zu Heringdorf, D., and Jakobs, K. H. (2007). Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. *Biochem. Biophys. Res. Commun.* 1768, 923ñ940. doi: 10.1016/j.bbrc.2006.09.026

Mitsuzaka, T., Atsumi, A., Matsumori, R., Nia, T., Shinozaki, H., Suzuki-Kemuriyama, N., et al. (2012). Elovl6 promotes nonalcoholic steatohepatitis. *Hepatology* 56, 2199ñ2208. doi: 10.1002/hep.25932

Meyer zu Heringdorf, D., and Jakobs, K. H. (2007). Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. *Biochem. Biophys. Res. Commun.* 1768, 923ñ940. doi: 10.1016/j.bbrc.2006.09.026

Murasaki, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T., and Yamamoto, K. (2011). Recent progress in phospholipase A2 research: from cells to animals to humans. *Prog. Lipid Res.* 50, 152ñ192. doi: 10.1016/j.plipres.2010.12.001

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., et al. (2018). Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. *Clin. Cardiol.* 41, 1281ñ1288. doi: 10.1002/clc.23055

Oster, R. T., Tishinsky, J. M., Yuan, Z., and Robinson, L. E. (2010). Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARY mRNA, in 3T3-L1 adipocytes. *Appl. Physiol. Nutr. Metab.* 35, 783ñ789. doi: 10.1139/h10-076

Petersen, M. C., and Shulman, G. I. (2018). Mechanisms of insulin action and insulin resistance. *Physiol. Rev.* 98, 2133ñ2223. doi: 10.1152/physrev.00063.2017

Rossmeisl, M., Medrikova, D., van Schothorst, E. M., Pavlisova, J., Kuda, O., Hensler, M., et al. (2014). Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. *Biochim. Biophys. Acta.* 1841, 267ñ278. doi: 10.1016/j.bbalip.2013.11.010

Schüchel, H., Schlüter, A., Golenbock, D. T., Latz, E., Martinez-Martinez, P., and Heneka, M. T. (2017). Activation of the NLRP3 inflammasome in microglia: the role of ceramide. *J. Neurochem.* 143, 534ñ550. doi: 10.1111/jnc.14225

Sers, C., Emmenegger, U., Husmann, K., Bucher, K., Andres, A. C., and Schäfer, R. (1997). Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. *J. Cell Biol.* 136, 935ñ944. doi: 10.1083/jcb.136.4.935

Tortosa-Caparrós, E., Navas-Carrillo, D., Marín, F., and Orenes-Piñero, E. (2017). Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. *Crit. Rev. Food Sci. Nutr.* 57, 3421ñ3429. doi: 10.1080/10408398.2015.1126549

Uyama, T., Morishita, J., Jinn, X. H., Okamoto, Y., Tsboi, K., and Ueda, N. (2009). The tumor suppressor gene H-rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type. *J. Lipid Res.* 50, 685ñ693. doi: 10.1194/jlr.m800453-jlr200

Wang, L., Chen, K., Wan, X., Wang, F., Guo, Z., and Mo, Z. (2017). NLRP3 inflammasome activation in mesenchymal stem cells inhibits osteogenic differentiation and enhances adipogenic differentiation. *Biochem. Biophys. Res. Commun.* 484, 871ñ877. doi: 10.1016/j.bbrc.2017.02.007

Zhang, S. Y., Dong, Y. Q., Wang, P., Zhang, X., Yan, Y., Sun, L., et al. (2018). Adipocyte-derived lysophosphatidylcholine activates adipocyte and adipose tissue macrophage nod-like receptor protein 3 inflammasomes mediating homocysteine-induced insulin resistance. *EBioMedicine* 31, 202ñ216. doi: 10.1016/j.ebiom.2018.04.022

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Zhang, Dong, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.